Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Well – I’ve tried all three, as well as alternatives ... to see what a practicing physician thinks is best. When comparing Hims vs Roman vs Keeps, I’ll focus on hair loss medicines, although ...

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted ...

In this video, I will talk about recent updates regarding Hims & Hers Health (NYSE: HIMS). Watch the short video to learn more, consider subscribing, and click the special offer link below.

Feb 24 (Reuters) - Hims & Hers (HIMS.N), opens new tab said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk (NOVOb.CO), opens new ...